Hamps Bio Limited has successfully obtained its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The certificate demonstrates the company's adherence to regulatory requirements governing share depositories and participant operations.

Regulatory Compliance Status

Bigshare Services Private Limited, serving as the company's Registrar and Share Transfer Agent (RTA), issued the certificate on April 04, 2026. The certificate confirms that Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 is not applicable to Hamps Bio Limited during the specified quarter.

Share Holding Structure

The certificate highlights that the entire shareholding of Hamps Bio Limited remains in dematerialised (demat) form. This complete dematerialisation of shares eliminates the need for physical share certificates and ensures seamless electronic trading and transfer of securities.

During the quarter ended March 31, 2026, Bigshare Services Private Limited confirmed that no requests for rematerialisation were received from any company members. This indicates investor satisfaction with the electronic format and smooth functioning of the depository system.

Corporate Communication

Company Secretary Komal Jain (Membership No. ACS A40470) formally communicated the certificate to BSE Limited on April 14, 2026. The company has also made the certificate available on its official website at www.hampsbio.com for stakeholder access and transparency.

Company Operations

Hamps Bio Limited operates manufacturing facilities at two locations in Gujarat. Unit-1 is situated at G.I.D.C. Industrial Estate near Atul Ltd. in Ankleshwar, while Unit-2 is located at Bhatpore G.I.D.C. in Surat. The company, previously known as Hamps Bio Pvt. Ltd., maintains its corporate identification number as L24233GJ2007PLC049692.

Hamps Bio Limited has successfully completed its strategic acquisition of HSDL Innovative Private Limited, marking a significant milestone in the company's expansion plans. The transaction, valued at INR 2.04 crore, was finalized on March 25, 2026, transforming HSDL Innovative Private Limited into a wholly owned subsidiary.

Acquisition Details

The acquisition involved the purchase of 100% paid-up equity share capital of HSDL Innovative Private Limited through a cash transaction. The company acquired the shares from existing shareholders of the target company for a total purchase consideration of INR 2,04,00,000 (Rupees Two Crore Four Lakhs only).

Regulatory Compliance

Hamps Bio Limited informed the BSE about the completion of this acquisition under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. This announcement serves as a continuation of the company's earlier communication dated February 14, 2026, when the acquisition plan was first disclosed to the stock exchanges.

The company has confirmed that all information required under Regulation 30 read with Schedule III of the SEBI Listing Regulations, along with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, was previously provided to the stock exchanges through their letter dated February 14, 2026.

Corporate Structure Impact

With the completion of this acquisition, HSDL Innovative Private Limited has become a wholly owned subsidiary of Hamps Bio Limited effective March 25, 2026. This strategic move strengthens Hamps Bio Limited's corporate structure and potentially expands its operational capabilities through the integration of HSDL Innovative Private Limited's business activities.

The acquisition documentation was signed by Komal Jain, Company Secretary & Compliance Officer of Hamps Bio Limited, who holds membership number ACS A40470. The company has made this information available on its official website at www.hampsbio.com for stakeholder reference.